| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10689-013-9646-7 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s10689-013-9646-7 |
| P698 | PubMed publication ID | 23640109 |
| P2093 | author name string | Janis Gardovskis | |
| Arvids Irmejs | |||
| Edvins Miklasevics | |||
| Gunta Purkalne | |||
| Uldis Teibe | |||
| Inta Liepniece-Karele | |||
| Andris Gardovskis | |||
| Genadijs Trofimovics | |||
| Grigorijs Plakhins | |||
| Signe Subatniece | |||
| P2860 | cites work | PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer | Q24600928 |
| An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom | Q24648357 | ||
| A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment | Q24803679 | ||
| Are BRCA1- and BRCA2-related breast cancers associated with increased mortality? | Q24804064 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer | Q31960178 | ||
| Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery | Q33723561 | ||
| Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia | Q34059765 | ||
| External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement | Q34075697 | ||
| Population-based validation of the prognostic model ADJUVANT! for early breast cancer | Q34412284 | ||
| Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. | Q35006280 | ||
| Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations | Q35100315 | ||
| BRCA mutation testing in determining breast cancer therapy | Q35619225 | ||
| PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. | Q36184231 | ||
| Prognosis of BRCA-associated breast cancer: a summary of evidence | Q37605624 | ||
| Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature | Q37662402 | ||
| Breast cancer assessment tools and optimizing adjuvant therapy. | Q37803121 | ||
| Genetic susceptibility to breast cancer | Q41130542 | ||
| A decision aid to assist in adjuvant therapy choices for breast cancer | Q42681645 | ||
| A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer | Q43074624 | ||
| Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy | Q43222794 | ||
| Adjuvant! Online as a decision-making tool in early breast cancer--a UK national survey | Q43483233 | ||
| Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations | Q43520691 | ||
| Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? | Q44732177 | ||
| Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. | Q46765380 | ||
| Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group | Q47189470 | ||
| Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. | Q50961614 | ||
| Breast Cancer Prognosis inBRCA1andBRCA2Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study | Q57265621 | ||
| Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q59567527 | ||
| A population-based validation of the prognostic model PREDICT for early breast cancer | Q83523872 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 683-689 | |
| P577 | publication date | 2013-12-01 | |
| P1433 | published in | Familial Cancer | Q15761917 |
| P1476 | title | Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients | |
| P478 | volume | 12 |
| Q45740123 | Breast cancer therapy planning - a novel support concept for a sequential decision making problem |
| Q64085723 | Communicating prognosis to women with early breast cancer - overview of prediction tools and the development and pilot testing of a decision aid |
| Q94553235 | Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer |
| Q64091965 | Prognostic models for breast cancer: a systematic review |
| Q90483236 | The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer |
| Q35224593 | Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis |
Search more.